Enterprise-Wide Disclosures (Tables)

12 Months Ended

Dec. 31, 2018

Enterprise-wide Disclosures [Abstract]

Schedule of Geographic Area Information

The following table presents consolidated revenues, including license fees, royalties, grant income, and other revenues, disaggregated by geography, based on the billing addresses of customers, or in the case of grant revenues based on where the governmental entities that fund the grant are located (in thousands).

	Year Ended December 31,
Geographic Area	2018		2017 (1)
United States	$	1,804	$	1,651
Foreign (2)		3,184		1,807
Total revenues	$	4,988	$	3,458

(1)	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.
(2)	Foreign revenues are primarily generated from grants in Israel.

The composition of BioTime’s long-lived assets, consisting of plant and equipment, net, between those in the United States and in foreign countries, as of December 31, 2018 and 2017, is set forth below (in thousands):

	December 31,
	2018 (1)		2017
Domestic	$	2,038	$	2,746
Foreign (2)		3,797		2,787
Total	$	5,835	$	5,533

(1)	Reflects the effect of the AgeX Deconsolidation.
(2)	Assets in foreign countries principally include laboratory equipment and leasehold improvements in Israel.

Schedule of Revenues Disaggregated by Source

The following table presents BioTime’s consolidated revenues disaggregated by source (in thousands).

	Year Ended December 31,
REVENUES:	2018		2017 (1)
Grant revenue	$	3,572	$	1,666
Royalties from product sales and license fees		392		389
Subscription and advertisement revenues (2)		691		1,395
Sale of research products and services		333		8
Total revenues	$	4,988	$	3,458

(1)	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.
(2)	These revenues were generated by LifeMap Sciences, a subsidiary of AgeX. The revenues shown for 2018 are for the period January 1, 2018 through August 29, 2018. As a result of the AgeX Deconsolidation on August 30, 2018, BioTime does not expect to recognize this type of revenue in subsequent accounting periods.

Schedule of Sources of Revenues

The following table shows BioTime’s major sources of revenues, as a percentage of total revenues, that were recognized during the years ended December 31, 2018, 2017, and 2016:

	Year Ended December 31,
Sources of Revenues	2018		2017
NIH grant income (1)		21.2%		5.0%
IIA (formerly OCS) grant income (Cell Cure, Israel)		50.4%		43.2%
Subscriptions, advertising, licensing and other (various customers) (2)		20.5%		49.4%
Sale of research products		4.2%		-%
Other		3.7%		2.4%

(1)	Reflects income from grants to BioTime from the National Institutes of Health (NIH).
(2)	For 2018 and 2017, one individual customer represents greater than 5% of total revenues.